Molecular Targeted Imaging in Oncology with Radioscintigraphy

David J. Yang and E. Edmund Kim

Division of Diagnostic Imaging, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, U.S.A.

A Note from the Editors

~W~ ~Y~ fhile PET imaging has garnered much of the 1/1/ attention in oncologic imaging, there have been r r parallel and exciting developments in more conventional gamma radioscintigraphy. Conventional radioscintigraphy with 99m-technetium offers a substantially lower cost alternative to PET both in terms of synthesis and in instrumentation. This chapter describes a ''platform technology'' in which a surprising variety of ligands can be chelated to technetium. Examples of oncologic agents already in pre-clinical testing are provided. The authors, who are leaders in the field of radioligand synthesis, demonstrate how this ''plug and play'' construct lends itself to automation and portends a future in which versatile radioligands, tailored to the individual needs of the patient, can be created on demand.

0 0

Post a comment